Structural basis for an unexpected mode of SERM-mediated ER antagonism.

Published

Journal Article

Tamoxifen is effective for the prevention and treatment of estrogen-dependent breast cancers, but is associated with an increased incidence of endometrial tumors. We report the crystal structure of the estrogen receptor alpha (ERalpha) ligand binding domain (LBD) bound to the structurally similar compound GW5638, which has therapeutic potential and does not stimulate the uterus. Like tamoxifen, GW5638 relocates the carboxy-terminal helix (H12) to the known coactivator-docking site in the ERalpha LBD. However, GW5638 repositions residues in H12 through specific contacts with the N terminus of this helix. In contrast to tamoxifen, the resulting increase in exposed hydrophobic surface of ERalpha LBD correlates with a significant destabilization of ERalpha in MCF-7 cells. Thus, the GW5638-ERalpha LBD structure reveals an unexpected mode of SERM-mediated ER antagonism, in which the stability of ERalpha is decreased through an altered position of H12. This dual mechanism of antagonism may explain why GW5638 can inhibit tamoxifen-resistant breast tumors.

Full Text

Duke Authors

Cited Authors

  • Wu, Y-L; Yang, X; Ren, Z; McDonnell, DP; Norris, JD; Willson, TM; Greene, GL

Published Date

  • May 13, 2005

Published In

Volume / Issue

  • 18 / 4

Start / End Page

  • 413 - 424

PubMed ID

  • 15893725

Pubmed Central ID

  • 15893725

International Standard Serial Number (ISSN)

  • 1097-2765

Digital Object Identifier (DOI)

  • 10.1016/j.molcel.2005.04.014

Language

  • eng

Conference Location

  • United States